Proactive Investors - Run By Investors For Investors

Successor sought to build £500mln company at SkinBioTherapeutics

Dr Cath O'Neill, CEO of  SkinBioTherapeutics PLC (LON:SBTX), says her successor will have the skills to take the company to commercialisation.
The boss, who invented the skin care technology and the SkinBiotix repair and protect cream, tells Proactive London "it's now the job of someone else with a different skillset to build the business into a £500mln company."
O'Neill has been with life sciences company since the beginning and is looking to return to her scientific roots.

 
Meet Location Sciences Group PLC, Itaconix Plc and Shield Therapeutics PLC at our event, London , 21 March 2019. Register here »
View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use